Kyprolis (Carfilzomib) Patent Expiration, LOE Window & CMS Spending
Kyprolis (Carfilzomib) by Amgen: FDA Orange Book core substance LOE 2027-01-20 (last listed 2041-10-29), 0 AB generics, $52.5M 2024 CMS Part D & Medicaid spend, and 16 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Amgen |
| FDA Application & Pathway | N202714 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2027-01-20 |
| Last Listed Patent or Exclusivity Date | 2041-10-29 |
| Orange Book Patents (*PED Extensions) | 10 patents (5 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $52.5M |
| 2024 Medicare Part D Spend | $17.7M |
| 2024 Medicaid Spend | $34.8M |
| Reported Wholesale Price Change (CA SB 17) | 16 WAC filings (max 27.0% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.